AUTHORS
Huiqiang Huang, MD, PhD, Jicheng Hong2, jiaowu Cao3, Gao Yan, PhD4, Xuan-Ye Zhang5, Huang He6, Jia-Ling Zhuang7, Xiujin Chen8
AFFILIATIONS
1 Sun Yat-sen University Cancer Center, Guangzhou, China
2 Sun Yat-sen University Cancer Center, Guangzhou, China
3 Sun Yat-sen University Cancer Center, Guangzhou, China
4 Sun Yat-sen University Cancer Center, Guangzhou, China
5 Sun Yat-sen University Cancer Center, Guangzhou, China
6 Sun Yat-sen University Cancer Center, Guangzhou, China
7 Sun Yat-sen University Cancer Center, Guangzhou, China
8 Sun Yat-sen University Cancer Center, Guangzhou, China
ABSTRACT
Background:
Relapsed/refractory (R/R) ALK-positive anaplastic large cell lymphoma (ALK+ ALCL) remains a therapeutic challenge with limited effective options following the failure of brentuximab vedotin (BV) or autologous stem cell transplantation (ASCT). ALK inhibitors (ALKi) have demonstrated promising activity in this setting. However, real-world data on ALKi-based strategies, particularly in heavily pretreated adult populations, remain limited. We conducted this retrospective analysis to evaluate the real-world efficacy and survival outcomes of ALKi monotherapy or in combination with chemotherapy in R/R ALK+ ALCL.
Methods:
This single-center retrospective study included R/R ALK+ ALCL patients treated at Sun Yat-sen University Cancer Center between January 2012 and December 2025. All patients received at least one ALKi-based regimen (monotherapy or combination with chemotherapy) and had evaluable responses. The primary endpoints were objective response rate (ORR) and complete response rate (CRR) per Lugano 2014 criteria. Secondary endpoints included progression-free survival (PFS) and overall survival (OS), estimated using the Kaplan-Meier method.
Results:
A total of 52 patients were enrolled, with 35 receiving ALKi monotherapy and 17 receiving ALKi plus chemotherapy. ALKi comprised crizotinib (first-generation, n=28) and second-generation agents (n=24), including iruplinalkib and ceritinib. At data cutoff, 8 patients remained on treatment. Median age was 30.0 years (range, 16–72). Baseline characteristics: stage IV, 63.5%; prior ASCT, 15.4%; prior BV, 53.9%; ≥2 prior lines, 36.5% (median, 2; range, 1–5). Median ALKi treatment duration was 8.8 months. The ORR and CRR were 88.5% (46/52) and 80.8% (42/52), respectively; one patient had stable disease and five had progressive disease. With a median follow-up of 20.0 months (range, 2.5–167.3), 9 deaths occurred; median OS was not reached. The 1-, 2-, and 5-year OS rates were 91.4% (95% CI, 83.6–99.8), 85.9% (95% CI, 75.9–97.2), and 67.4% (95% CI, 48.6–93.5), respectively. Twelve patients experienced disease progression; median PFS was not reached. The 1-, 2-, and 5-year PFS rates were 79.1% (95% CI, 68.4–91.6), 76.6% (95% CI, 65.3–89.9), and 71.5% (95% CI, 58.0–88.1), respectively. The toxicity was predominantly grade 1–2 diarrhea and hypertension, with grade 1–2 creatinine elevation also observed; no grade ≥3 adverse events were noted.
Conclusions:
ALK inhibitors demonstrate durable, robust responses and favorable long-term survival in R/R ALK+ adult ALCL, even in heavily pretreated patients. These real-world data support the use of ALKi as a vital treatment strategy in this population. Prospective trials are warranted to optimize combination approaches and elucidate mechanisms of resistance.
DISCLOSURES
Huiqiang Huang, MD, PhD: No relevant conflicts of interest to declare.